Evidence map›Paper›PMID 42028833›Full record

ArticleMolecular pharmaceutics2026

Predicting Agitation Stability of Monoclonal Antibodies during Developability Assessment.

Michaela Cohrs, Nevena Pagureva, Utku Ozbulak, Wesley De Neve, Kevin Braeckmans, Stefaan De Smedt, Slavka Tcholakova, Zahari Vinarov, Hristo L Svilenov

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michaela CohrsLaboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.ORCID 0000-0003-1195-534X
Nevena PagurevaDepartment of Chemical and Pharmaceutical Engineering, Faculty of Chemistry and Pharmacy, Sofia University, 1 J. Bourchier Ave., 1164 Sofia, Bulgaria.
Utku OzbulakCenter for Biosystems and Biotech Data Science, Ghent University, Global Campus, 119-5 Songdomunhwa-ro, Incheon 21985, Republic of Korea.
Wesley De NeveCenter for Biosystems and Biotech Data Science, Ghent University, Global Campus, 119-5 Songdomunhwa-ro, Incheon 21985, Republic of Korea.
Kevin BraeckmansLaboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.ORCID 0000-0002-7993-6295
Stefaan De SmedtLaboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.ORCID 0000-0002-8653-2598
Slavka TcholakovaDepartment of Chemical and Pharmaceutical Engineering, Faculty of Chemistry and Pharmacy, Sofia University, 1 J. Bourchier Ave., 1164 Sofia, Bulgaria.ORCID 0000-0001-8091-7529
Zahari VinarovDepartment of Chemical and Pharmaceutical Engineering, Faculty of Chemistry and Pharmacy, Sofia University, 1 J. Bourchier Ave., 1164 Sofia, Bulgaria.
Hristo L SvilenovBiopharmaceutical Technology, TUM School of Life Sciences, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany.ORCID 0000-0001-5863-9569

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developability assessment facilitates the selection of antibody drug candidates with desirable pharmaceutical properties. However, it remains uncertain whether agitation-induced aggregation can be predicted from standard developability parameters. Here, we investigated whether key biophysical parameters predict agitation-induced aggregation of monoclonal antibodies (mAbs). To this end, we generated a benchmark data set by characterizing the aggregation upon agitation in the presence of an air-liquid interface of ten approved mAbs reformulated in a common surfactant-free buffer. The extent of aggregation varied substantially among mAbs and was primarily dependent on antibody identity. Flow imaging microscopy combined with machine learning revealed micrometre-sized aggregates with distinct morphologies, consistent with aggregation at air-liquid interfaces. Examination of thin liquid films and foams confirmed the presence of aggregates directly at the air-liquid interface and, therefore, the critical role of this interface for antibody aggregation during agitation. We then applied fluorescence-based, light scattering, and chromatographic techniques to determine standard developability parameters for each mAb, including apparent melting temperature (

Indexed as

Antibodies, MonoclonalDrug StabilityHydrophobic and Hydrophilic InteractionsProtein StabilityAntibodies, Monoclonalantibody drugsbiophysical characterizationdevelopabilityinterfacial rheologyinterfacial stabilitysurface tension

Identifiers

PMID42028833
PMCPMC13231419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.